Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic. Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product ...
Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...
Vertex Pharmaceuticals said Thursday that its closely watched drug, suzetrigine, reduced pain compared to baseline but did not outperform a placebo in a Phase 2 study, raising doubts about the ...
Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback